Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | GRK1 | Q15835 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059746 | 0.88 | GRK2 (0.50) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12059006 | 0.86 | RAB9A (0.54) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2054370 | 0.85 | KMT2A (0.46) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3505879 | 0.84 | MAPT (0.47) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6922019 | 0.81 | GRM2 (0.51) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24166042 | 0.80 | TNF (0.61) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6921490 | 0.80 | LMNA (0.54) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3504325 | 0.77 | MAOB (0.48) | MAPTMAPK1HTTSMN1; SMN2KMT2A | |
| SCHEMBL6921950 | 0.77 | MAPK14 (0.47) | MAPTALDH1A1GAAKMT2APIK3CA | |
| SCHEMBL6922028 | 0.76 | SLC2A1 (0.52) | MAPTMAPK1ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | MAPT 298/4885MAPK1 1459/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.